Topiramate for neuropathic pain and fibromyalgia in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Wiffen, Philip J ^a   Derry, Sheena ^a   Lunn, Michael P T ^b   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; PLACEBO; TOPIRAMATE;

ARTHRALGIA; COMPLEX REGIONAL PAIN SYNDROME; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; LEG CRAMP; NAUSEA; NEUROPATHIC PAIN; PARESTHESIA; PHANTOM PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL; TRIGEMINUS NEURALGIA; WEAKNESS;

EID: 84893420311     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008314.pub3     Document Type: Review

References (78)

1. Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. Topiramate in chronic lumbar radicular pain. Journal of Pain 2005;6(12):829-36. [DOI: 10.1016/j.jpain.2005.08.002; PUBMED: 16326371]
2. Freeman R. A double-blind, placebo-controlled, parallel group study to evaluate the effect of topiramate on electrophysiologic parameters in subjects with diabetic peripheral polyneuropathy. apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00231673 (accessed 9 May 2013).
3. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al (CAPSS-141 Study Group). Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004;63(5):865-73. [DOI: 10.1212/01.WNL.0000137341.89781.14; PUBMED: 15365138]
4. Thienel U, Neto W, Schwabe SK, Vijapurkar U, Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurologica Scandinavica 2004;110(4):221-31. [DOI: 10.1111/j.1600-0404.2004.00338.x; PUBMED: 15355485]
5. Edwards KR, Glantz MJ, Levin P. An evaluation of topiramate in the management of painful diabetic neuropathy. American Pain Society 17th Annual Scientific Meeting, San Diego November 5-8. 1998.
6. Edwards KR, Glantz MJ, Button J, Norton JA, Whittaker T, Cross N. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Neurology. 2000; Vol. 54 (Suppl 3):A81.
7. Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain 2006;22(6):526-31. [DOI: 10.1097/.ajp.0000192516.58578.a4]
8. Vinik A, Hewitt D, Xiang J, Jordan D, Rosenthal N. Topiramate in the treatment of painful diabetic neuropathy: results from a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 2003; Vol. 60 (Suppl 1):A154-5.
9. National Institute of Dental and Craniofacial Research (NIDCR). Studies of dextromethorphan and topiramate to treat oral and facial pain. clinicaltrials.gov/show/NCT00001725 2002 (accessed 9 May 2013).
10. Wang QP, Bai M. Topiramate versus carbamazepine for the treatment of classical trigeminal neuralgia: a meta-analysis. CNS Drugs 2011;25(10):847-57. [DOI: 10.2165/11595590-000000000-00000; PUBMED: 21936587]
11. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handbook of Experimental Pharmacology 2012;209:433-66. [DOI: 10.1007/978-3-642-24716-3_20]
12. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49-64. [DOI: 10.1016/j.pain.2010.11.010]
13. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113-e88. [DOI: 10.1111/j.1468-1331.2010.02999.x]
14. Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009485.pub2]
15. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7. [DOI: 10.1016/j.pain.2007.08.013]
16. Carroll DG, Kline KM, Malnar KF. Role of topiramate for the treatment of painful diabetic peripheral neuropathy. Pharmacotherapy 2004;24(9):1186-93.
17. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. The Clinical Journal of Pain 2003;19(1):59-68.
18. Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2]
19. Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009486.pub2]
20. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111]
21. Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
22. Donofrio PD, Raskin P, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al (CAPSS-141 Study Group). Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clinical Therapeutics 2005;27(9):1420-31. [DOI: 10.1016/j.clinthera.2005.09.011]
23. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
24. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009183.pub2]
25. Green MW, Seeger JD, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. Headache 2012;52(7):1070-84. [DOI: 10.1111/j.1526-4610.2012.02190.x]
26. GustorffB, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132-6. [DOI: 10.1111/j.1399-6576.2007.01486.x]
27. Gutierrez-Alvarez AM, Beltrán-Rodríguez J, Moreno CB. Antiepileptic drugs in treatment of pain caused by diabetic neuropathy. Journal of Pain and Symptom Management 2007;34(2):201-8. [DOI: 10.1016/j.jpainsymman.2006.10.023]
28. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26]
29. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
30. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [PUBMED: 8721797]
31. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204-5. [DOI: 10.1016/j.pain.2011.06.017]
32. Jette N, Hemming K, Hutton JL, Marson AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD001417.pub2]
33. Kanda T, Kurokawa M, Tamura S, Nakamura J, Ishii A, Kuwana Y, et al. Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sciences 1996;59(19):1607-16. [PUBMED: 8913326]
34. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10(5-6):276-81.
35. Khaliq W, Alam S, Puri NK. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2]
36. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7. [DOI: 10.1016/j.pain.2009.08.023]
37. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain--differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55]
38. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
39. Lunn MP, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2]
40. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Diseases in Canada 2006;27(1):9-16.
41. McQuay H, Moore R. An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]
42. McQuay HJ, Smith LA, Moore RA. Chronic Pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews: Third Series. Oxford: Radcliffe Publishing Ltd, 2007. [ISBN: 978-1-84619-063-6]
43. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. NeuroImage 2007;37 Suppl 1:S80-8. [DOI: 10.1016/j.neuroimage.2007.03.054]
44. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [PUBMED: 9870574]
45. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
46. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
47. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al."Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [PUBMED: 20627575]
48. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]
49. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013]
50. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
51. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2]
52. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]
53. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
54. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
55. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
56. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2013 March 6 [Epub ahead of print]. [DOI: 10.1111/papr.12050]
57. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
58. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]
59. O'Connor, AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine 2009;122(10 Suppl):S22-32. [DOI: 10.1016/j.amjmed.2009.04.007]
60. Cochrane Pain, Palliative and Supportive Care Group (PaPaS). PaPaS author and referee guidance. http://papas.cochrane.org/papas-documents (accessed 22 January 2013).
61. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56(2):127-38. [PUBMED: 8008402]
62. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
63. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice 2013 March 28 [Epub ahead of print]. [DOI: 10.1111/papr.12054]
64. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community-based study. Arthritis & Rheumatism 2013 April 1 [Epub ahead of print]. [DOI: 10.1002/art.37962]
65. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
66. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia--responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150]
67. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
68. Sun C, Lay C, Broner S, Silberstein S, Tepper S, Newman L. Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache 2006;46(9):1450-3. [DOI: 10.1111/j.1526-4610.2006.00587.x]
69. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281-9. [DOI: 10.1016/j.jpain.2005.11.008]
70. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews. Neurology 2011;7(3):173-81. [DOI: 10.1038/nrneurol.2011.4]
71. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5. [DOI: 10.1212/01.wnl.0000282763.29778.59]
72. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
73. Walia KS, Khan EA, Ko DH, Raza SS, Khan YN. Side effects of antiepileptics - a review. Pain Practice 2004;4(3):194-203. [PUBMED: 17173601]
74. Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3]
75. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD005451.pub2]
76. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006044.pub3]
77. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33(2):160-72. [PUBMED: 2306288]
78. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research 2010;62(5):600-10. [DOI: 10.1002/acr.20140]